CommercialCoverageMedium impact
08.01.93e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease
Independence Blue Cross·Neurology, Geriatrics, Internal Medicine·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
This is a reissued medical policy on monoclonal antibodies directed against amyloid for Alzheimer disease treatment, effective March 5, 2025. The billing team must review coverage criteria, prior authorization requirements, and applicable billing codes for amyloid-targeting monoclonal antibody therapies to ensure compliant claims processing.
Action Required
By March 5, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-93e to identify specific CPT/HCPCS codes for amyloid-directed monoclonal antibodies (e.g., aducanumab, lecanemab, donanemab). Update billing software with prior authorization rules and coverage limitations as specified in the policy. Notify providers of any new documentation requirements for Alzheimer disease diagnosis and amyloid positivity confirmation. Flag claims for these drugs submitted before policy review to prevent denials.